U.S. Electronic Equipment and Components Stock News

MasterBrand (MBC) opened Q1 2026 with revenue of US$618 million and a basic EPS loss of US$0.12, while trailing 12 month figures show revenue of about US$2.7 billion and a marginal basic EPS loss of US$0.02, underscoring pressure on profitability. Over recent quarters the company has seen revenue move between US$660.3 million in Q1 2025 and US$730.9 million in Q2 2025, alongside basic EPS shifting from a profit of US$0.29 in Q2 2025 to a loss of US$0.33 in Q4 2025. This sets the stage for...

Citigroup is holding its first Investor Day in four years today, where senior leaders are expected to outline new profitability targets, AI deployment plans, and updates on risk-management remediation and capital returns. This rare investor forum offers a consolidated view of how management intends to balance technology investment, operational efficiency, and shareholder returns across the global franchise. We’ll now look at how the Investor Day focus on higher profitability targets and AI...

Veracyte (VCYT) just posted Q1 2026 results with revenue of US$139.1 million and basic EPS of US$0.36, while trailing 12 month figures show revenue of US$541.7 million and basic EPS of US$1.11, alongside a 166.3% year over year earnings increase and net margins at 16.2% versus 7.1% a year earlier. Over recent quarters the company has seen revenue move from US$114.5 million in Q1 2025 to US$139.1 million in Q1 2026, with basic EPS ranging from US$0.09 to US$0.52 in interim periods. This sets...

Jazz Pharmaceuticals (JAZZ) opened 2026 with Q1 revenue of US$1.1 billion and basic EPS of US$4.74, setting a clear marker against last year’s volatile run of quarterly results. Over recent quarters the company has seen revenue move from US$897.8 million in Q1 2025 to US$1.09 billion in Q4 2024 and then to US$1.07 billion in Q4 2025. Basic EPS has shifted from a loss of US$1.52 per share in Q1 2025 to US$3.16 in Q4 2024 and US$3.33 in Q4 2025, leaving investors focused on how much of the...

Deluxe (DLX) opened 2026 with Q1 revenue of US$538.1 million and basic EPS of US$0.77. Trailing 12 month figures show revenue of US$2.1 billion and EPS of US$2.31, supported by 85.5% earnings growth over the past year. Over recent quarters the company has seen revenue fluctuate in a tight band between US$520.6 million and US$540.2 million, with basic EPS ranging from US$0.26 to US$0.77, and net profit margins over the last 12 months running at 4.9% versus 2.6% in the prior year. This sets up...

If you are wondering whether L3Harris Technologies at around US$302 a share looks expensive or attractive, the next step is to line that price up against what the business might reasonably be worth. The stock has seen a 6.0% decline over the last 7 days and a 15.8% decline over the last 30 days, even though the 1 year return sits at 41.0% and the 3 year return at 70.1%. Recent headlines have focused on L3Harris Technologies as a key player in aerospace and defense programs and contract...

Vontier (NYSE:VNT) highlighted its multi energy fleet technology strategy at ACT Expo 2026. The company presented an integrated platform that combines traditional and new energy refueling, EV management, diagnostics, payment security, and telematics. The event showcased new solutions aimed at supporting fleet decarbonization and digital transformation. For investors tracking the fleet and mobility sector, Vontier sits at the intersection of hardware, software, and services for...

Kyndryl Holdings (KD) just closed FY 2026 with fourth quarter revenue of US$3.8b and basic EPS of US$0.08, alongside trailing 12 month revenue of US$15.1b and EPS of US$0.87 that frame the full year picture. Over recent quarters, revenue has moved in a tight band from US$3.7b to US$3.9b while quarterly EPS has ranged from US$0.24 to US$0.29 before landing at US$0.08 in Q4, giving you a clear sense of how earnings have tracked against a largely steady top line. With a trailing net profit...

Primoris Services (PRIM) opened 2026 with Q1 revenue of US$1.6b and basic EPS of US$0.32, setting the tone for how its construction and infrastructure pipeline is feeding through to the bottom line. Over the past year, revenue has moved from US$1.6b in Q1 2025 to US$1.9b in Q2 2025, US$2.2b in Q3 2025, US$1.9b in Q4 2025 and US$1.6b in Q1 2026, while quarterly basic EPS has ranged from US$0.82 to US$1.75 across those periods. For investors, a key focus is how these volumes are translating...

Qorvo (QRVO) has just closed out FY 2026 with fourth quarter revenue of US$808.3 million and basic EPS of US$0.32, capping a year in which trailing twelve month revenue reached about US$3.7 billion and EPS came in at US$3.66. Over recent quarters the company has seen revenue range from US$808.3 million to US$1.1 billion and basic EPS move between US$0.28 and US$1.77, with trailing net income over the last twelve months totaling US$339.0 million. For investors, the key takeaway is that margins...

InTest (INTT) opened 2026 with Q1 revenue of US$33.9 million and basic EPS of US$0.06, while the trailing twelve months show total revenue of US$121.1 million and basic EPS of US$0.05, giving investors a clear snapshot of current scale and per share profitability. The company has seen quarterly revenue move from US$26.6 million in Q1 2025 to US$33.9 million in Q1 2026, with basic EPS shifting from a loss of US$0.19 to a profit of US$0.06 over the same period. This sets up a results season...

Coherent (NYSE:COHR) announced that Chief Strategy Officer Giovanni Barbarossa will transition from his role and retire in September 2026. Barbarossa will serve as Special Advisor to the CEO until his retirement, supporting continuity during the leadership change. The announcement comes alongside Coherent reporting revenue and earnings growth across its business. Coherent is a supplier of advanced optics and laser technologies that are used in AI infrastructure, communications, and...

QuidelOrtho (QDEL) opened Q1 2026 with revenue of US$619.8 million and a basic EPS loss of US$1.35, while trailing 12 month figures show revenue of US$2.66 billion against a basic EPS loss of US$17.81. Over the past six reported quarters, revenue has ranged from US$613.9 million to US$723.6 million, and quarterly basic EPS has moved between a loss of US$0.19 and a loss of US$10.78. This leaves investors focused on how much of today’s revenue base can ultimately translate into more stable...

Kinder Morgan (NYSE:KMI) is facing a lawsuit in Texas alleging gross negligence after a pipeline explosion that severely injured a worker. The legal action claims inadequate safety protocols and seeks to preserve the explosion site for investigation under a temporary restraining order. The case focuses on operational safety practices and potential liability exposure for the pipeline operator. Kinder Morgan operates energy infrastructure assets, including pipelines that transport natural gas...

Hinge Health (HNGE) opened Q1 2026 with revenue of $182.3 million and basic EPS of $0.43, providing a clear view of how the business is currently converting its top line into per share results. Over the past year, the company has reported quarterly revenue of $117.3 million in Q4 2024, $123.8 million in Q1 2025, $139.1 million in Q2 2025, $154.2 million in Q3 2025, $170.7 million in Q4 2025 and now $182.3 million in Q1 2026. Basic EPS over the same period has ranged from $1.98 to $7.38,...

Phibro Animal Health Corporation has reported its third-quarter 2026 results, with sales of US$383.54 million and net income of US$24.02 million, alongside the launch of its Sustainable Solutions Platform and Verratain™ low‑carbon feed products in partnership with VAXA Technologies. The combination of stronger earnings and a companywide push into emissions‑focused feed ingredients suggests Phibro is tying profitability more closely to sustainability trends across animal protein and petfood...

Bloomin' Brands (BLMN) opened 2026 with Q1 revenue of US$1.1b and basic EPS of US$0.65, setting the tone for how investors will read its latest earnings story against a current share price of US$8.12. The company has seen quarterly revenue move from US$972.0m in Q4 2024 to US$1.1b in Q1 2026, while basic EPS has ranged from US$0.13 in Q4 2024 to a loss of US$0.54 in Q3 2025 and then back to US$0.65 in the latest quarter. This puts the focus squarely on how durable any margin recovery really...

Coty (COTY) Q3 2026: Earnings Snapshot Coty (COTY) has just posted its Q3 2026 numbers, with revenue of US$1.3 billion, basic EPS of a US$0.47 loss, and a net income loss of US$411.4 million setting the tone for the quarter. Over recent periods the company has seen quarterly revenue move from US$1.3 billion in Q3 2025 to US$1.3 billion in Q3 2026, with basic EPS unchanged at a US$0.47 loss. Trailing twelve month EPS stand at a US$0.62 loss and net income at a US$545.8 million loss, which...

Millrose Properties (MRP) opened Q1 2026 with total revenue of US$194.9 million and basic EPS of US$0.74, while trailing 12 month revenue stood at US$712.7 million and EPS at US$2.79 as the company continued to build on its recent return to profitability. The company has seen revenue move from US$82.7 million in Q1 2025 to US$194.9 million in Q1 2026, with basic EPS shifting from US$0.39 to US$0.74 over the same period. This sets up a story where investors are weighing the earnings recovery...

Oscar Health (OSCR) has opened 2026 with a sharp swing into profitability in its latest quarter, posting Q1 revenue of about US$4.6 billion alongside basic EPS of US$2.28 on net income of roughly US$679 million, versus Q1 2025 revenue of about US$3.0 billion and EPS of US$1.10. Over the trailing twelve months to Q1 2026, revenue has moved from roughly US$9.2 billion to about US$13.3 billion, while EPS on the same basis shifted from US$0.11 to a small loss of US$0.14, highlighting how the...

What recent performance tells you about Roivant Sciences Roivant Sciences (ROIV) has drawn fresh attention after recent trading, with the stock last closing at US$28.82 and posting gains over the past week, month and past 3 months. For investors, the move comes against a backdrop of clinical-stage drug development, a market value of about US$20.27b and reported annual revenue of US$13.31 million alongside a net loss of US$809.24 million. See our latest analysis for Roivant Sciences. These...

Teradata (TDC) opened 2026 with Q1 revenue of US$444 million and basic EPS of US$3.60, against a backdrop of trailing 12 month revenue of US$1.69 billion and EPS of US$4.48, where earnings over that period are reported to have grown very strongly year over year. Over recent quarters, revenue has moved from US$409 million in Q4 2024 to US$418 million in Q1 2025 and US$421 million in Q4 2025, while quarterly EPS has ranged between roughly US$0.09 and US$0.46 before this latest jump. This sets...

In late April 2026, MetLife, Inc. announced that its board approved a second-quarter 2026 common stock dividend of US$0.5925 per share, a 4.4% increase from the prior quarter, payable on June 9, 2026, to shareholders of record as of May 12, 2026. This latest increase adds to a long-running pattern of dividend growth since 2011, underlining the company’s emphasis on returning cash to shareholders through regular income. Next, we’ll examine how MetLife’s higher quarterly dividend, and its...

Earnings and convertible notes set the stage for Ocugen stock Ocugen (OCGN) is back in focus after reporting first quarter 2026 results and closing a US$103.5 million convertible note offering, a combination that puts both its cash needs and capital structure in the spotlight. See our latest analysis for Ocugen. The recent 1 day share price return of 2.35% decline and 7 day share price return of 13.39% decline suggest some short term profit taking after the earnings release and convertible...